Foreign-made drugs could soon face 100% US import tariffs, but that figure is likely an opening bid in negotiations — and there are still compelling ways to invest in healthcare, Impax Asset Management’s Nathan Moser says
Foreign-made drugs could soon face 100% US import tariffs, but that figure is likely an opening bid in negotiations — and there are still compelling ways to invest in healthcare, Impax Asset Management’s Nathan Moser says pic.twitter.com/XyNswjK2MW
— Reuters (@Reuters) September 29, 2025